Uptravi selexipag regulatory update

The European Commission approved an MAA from Actelion for Uptravi selexipag for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with World Health Organization (WHO) functional class II-III. The long-acting prostacyclin (IP) receptor ( PGI2; PTGIR) agonist is indicated as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist and/or a phosphodiesterase-5 (PDE-5) inhibitor or as monotherapy in patients who are not candidates for these therapies. Actelion plans to launch Uptravi in the EU “as soon as possible,” starting with Germany. ...